Reversion from transformed to normal phenotype by inhibition of protein synthesis in rat kidney cells infected with a temperature-sensitive mutant of Rous sarcoma virus.
By the use of a rat kidney cell line infected with a temperature-sensitive Rous sarcoma virus, we have shown that, at permissive temperatures where the cells are transformed, concanavalin A induces a clustering of its cell membrane receptors into patches, and the intracellular smooth muscle myosin-like protein is in a disordered state. By contrast, with infected cells grown at nonpermissive temperatures, the addition of concanavalin A does not alter the uniform distribution of its receptors, and the smooth muscle myosin-like protein is arranged in an ordered filamentous structure. These results are consistent with the hypothesis that the myosin protein is part of an intracellular aggregating-disaggregating complex. In the normal cell it is in its aggregated state and inhibits the lateral mobility of the concanavalin A receptors in the membrane; in the transformed cell the complex is relatively disaggregated and permits the concanavalin A receptors to be mobile. The addition of protein synthesis inhibitors to infected cells grown at the permissive temperature causes the cell to change from the transformed phenotype to the normal. Removal of the reversible inhibitors causes the cells to revert to the transformed phenotype. These results show that (i) protein synthesis, presumably of an unstable product of the transforming gene of the temperature-sensitive virus, is required to maintain the transformed state in these infected cells at the permissive temperature; and (ii) protein synthesis is not required for the intracellular myosin-containing complex to revert from its disordered transformed state to its ordered normal state. This suggests that the product of the transforming gene directly or indirectly causes the disaggregation of the myosin-containing complex in the process of transformation.
D000036:Abrin / Q000494:pharmacology; D001358:Avian Sarcoma Viruses; D002460:Cell Line; D002462:Cell Membrane / Q000648:ultrastructure; D002471:Cell Transformation, Neoplastic; D003285:Contractile Proteins / Q000378:metabolism*; D003513:Cycloheximide / Q000494:pharmacology; D009154:Mutation; D009218:Myosins; D011691:Puromycin / Q000494:pharmacology; D011952:Receptors, Concanavalin A / Q000378:metabolism*; D011955:Receptors, Drug / Q000378:metabolism*; D013696:Temperature
D003285:Contractile Proteins; D011952:Receptors, Concanavalin A; D011955:Receptors, Drug; D000036:Abrin; D011691:Puromycin; D003513:Cycloheximide; D009218:Myosins